Study tests combo prostate cancer therapy with radium-223 | Experts: DNA colon cancer test may be effective, but false-negative rate unknown | Certain oral bacteria signal pancreatic cancer risk, study finds
April 26, 2016
CONNECT WITH SNMMI
News for nuclear medicine and molecular imaging professionals
A midstage study is evaluating treatment with sipuleucel-T alone, compared with sipuleucel-T plus radium-223 in patients with castration-resistant prostate cancer that has spread to bone but with no visceral involvement. Dr. Jong Chul Park hypothesizes that "we can enhance the immune response and that may actually transfer into improved clinical outcomes. We may see some objective responses if we induce a strong enough immune response."
A study to be presented at the American Academy for Cancer Research's annual meeting showed the stool-based colon cancer DNA test Cologuard may be effective, but experts questioned the sensitivity of the test for precancerous polyps and warned that the size of the study, which included just 46 patients, is too small to draw strong conclusions about Cologuard. "Not all colon cancers have the predetermined DNA mutations measured by Cologuard, meaning that other cancers may be missed by this test and we do not know the false-negative rate of Cologuard," said Dr. David Bernstein of Northwell Health in Manhasset, N.Y.
The presence of Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans bacteria in the mouth might signal risk of developing pancreatic cancer, researchers at NYU Langone Medical Center said at the American Association for Cancer Research Annual Meeting. Study participants with P. gingivalis in the mouth were 59% more likely to develop pancreatic cancer, and those with A. actinomycetemcomitans were at 50% higher risk, the researchers reported. Both bacteria are associated with periodontitis, and the findings might lead to new approaches to preventing pancreatic cancer.
A five-year oncology research agreement has been formed between AbbVie and the University of Chicago that will focus on various cancers, including lung, colorectal and hematological. Under the agreement, AbbVie will fund preclinical research and clinical studies at the university and have the option to exclusively license discoveries arising from the collaboration.
Spectrum Pharmaceuticals' Evomela, or melphalan, secured seven-year orphan drug exclusivity from the FDA. Evomela was approved by the agency in March and is indicated as a high-dose conditioning therapy for multiple myeloma patients who will undergo a hematopoietic stem cell transplant.
Creating an online portal with evidence-based materials to help educate primary care physicians and students about pediatric migraine treatment may improve patient outcomes, researchers said at the American Academy of Neurology's annual meeting. At one school district, using the portal increased the number of patients with migraine getting preventive medication from 33% to 49%.
The University of Hawaii Cancer Center has been given three grants totaling about $3 million from the Defense Department to continue its studies on mesothelioma, a form of cancer that affects many veterans. One study is focusing on identifying gene mutations that can increase the risk for mesothelioma, while another looks at a protein that could be a biomarker to predict one's risk of developing the disease. A third study is examining the use of an antigen vaccine as a possible therapy.
Health systems planning to integrate predictive algorithms into their routine patient care should determine which clinical situations will benefit from these algorithms and leverage data from EHRs, write Ravi Parikh, Ziad Obermeyer and David Westfall Bates from Harvard Medical School. Focusing on low-value clinical decision points would prevent physicians from overtreating or undertreating patients, while not forcing predictive analytics into the existing workflow would allow physicians to integrate the algorithms more smoothly into patient care.
Join Nanci A. Burchell and Missy Stump on Thursday, May 19, at 3 p.m. ET for a complimentary member-only webinar: "Current Practices in Pediatric Nuclear Medicine." They will examine the current state of pediatric imaging, describe how three common pediatric imaging procedures differ from adult imaging and identify issues and/or controversies in pediatric practice. Free registration available for SNMMI-TS members. Register today.
SNMMI members, login to view your free digital copy of Myocardial Perfusion Imaging 2016: Quality, Safety, and Dose Optimization. This new digital publication offers comprehensive coverage of myocardial perfusion imaging, with particular focus on ways to improve quality, increase safety and reduce radiation burden. Log in and view your copy.
You are too important to the bigger picture to just fall off the canvas.
Johnnie Dent, writer
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at firstname.lastname@example.org.